Antibacterial drug discovery: Is it all downhill from here?

Clinical Microbiology and Infection, Supplement

Volumn 10, Issue 4, 2004, Pages 18-22

  Projan, Steven J ^a   Shlaes, D M ^b  

^a PFIZER INC   (United States)

^b Idenix Pharmaceuticals Inc   (United States)

Author keywords

Antiinfective drug discovery; Drug pricing; Generic competition; Industry productivity; Resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENERIC DRUG; ISONIAZID; LINEZOLID; MACROLIDE; NALIDIXIC ACID; NEW DRUG; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOTECHNOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; COMPETITION; DEPRESSION; DRUG CLASSIFICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; HEALTH CARE COST; HEALTH CARE NEED; HOSPITAL INFECTION; HUMAN; PRIORITY JOURNAL; PROFIT; QUALITY CONTROL; RESOURCE ALLOCATION; DRUG COST; DRUG RESISTANCE; HISTORY OF MEDICINE; DRUG DESIGN; ECONOMICS; PHARMACEUTICS; REVIEW;

ARGYROSOMUS REGIUS; BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 15544384259     PISSN: 14709465     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1465-0691.2004.1006.x     Document Type: Article

References (18)

1. Archer GL. Why do we REALLY need antibacterial drugs ICAAC Annual Meeting, Chicago 2003: Abstract 1123.
2. Wenzel RP, Sahm DF, Thornsberry C, Draghi DC, Jones ME, Karlowsky JA. In vitro susceptibilities of Gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-01 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Antimicrob Agents Chemother 2003; 47: 3089-98.
3. Livermore DM, James D, Reacher M, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales 1990-99. Emerg Infect Dis 2002; 8: 473-8.
4. Bromiker R, Arad I, Peleg O, Preminger A, Engelhard D. Neonatal bacteremia: patterns of antibiotic resistance. Infect Control Hosp Epidemiol 2001; 22: 767-70.
5. National Nosocomial Infections Surveillance, Report: data summary from October 1986-April 1996. Am J Infect Control 1996; 24: 380-8.
6. Crook DWM, Spratt BG. Multiple antibiotic resistance in Strcptococcus pneumoniae. Br Med Bull 1998; 54: 595-610.
7. Shlaes DM, Levy S, Archer G. Antimicrobial resistance: new directions. Am Soc Microbiol News 1991; 57: 455-8.
8. Lederberg J, Shope RE, Oaks SC Jr, eds. Emerging Infections. Microbial Threats to Health in the United States. National Academy Press 1992.
9. Peck C. Drug Development: Improving the Process. Food Drug Law Journal, 1997, 52.
10. DiMasi JA. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther 2001; 69: 286-96.
11. US Food and Drug Administration. Labeling requirements for systematic antibacterial drug products intended for human use. 21 CFR Part 201 Docket, 00N-146, 2003.
12. Stewart JJ, Allison PN, Johnson RS. Putting a price on biotechnology. Nature Biotechnol 2001; 19: 813-7.
13. Keim KL, Calcagno J, Leventer SM, Harris HW. Unlocking the value of failed CNS trials. Curr Drug Dis 2003; 3: 29-33.
14. DiMasi JA. Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 2001; 69: 297-307.
15. Hackbarth CJ, Chen DZ, Lewis JG et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother 2002; 46: 2752-64.
16. Payne DJ, Miller WH, Berry V, et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother 2002; 46: 3118-24.
17. Levy SB. The Antibiotic Paradox: How the Misuse of Antibiotics Destroys Their Curative Powers, 2nd edn. Cambridge, MA, Perseus Publishing, 2002.
18. US Food and Drug Administration, IDSA, /PhRma/FDA, Working Group Meeting 2002; November 19-20. Available at: http://www.fda.gov/cder/present/idsaphrma/default.htm.